Today: 15 May 2026
UOB stock price wobbles after JPMorgan downgrade as MAS review and earnings near
27 January 2026
2 mins read

UOB stock price wobbles after JPMorgan downgrade as MAS review and earnings near

Singapore, January 27, 2026, 14:50 (SGT) — Regular session.

United Overseas Bank Ltd (UOB) (SGX:U11) shares dipped 0.3% to S$38.40 by 2:48 pm in Singapore, underperforming its local peers as the market climbed. DBS Group advanced around 1.5%, and OCBC rose 1.3%, while the FTSE Straits Times Index gained about 1%. UOB is currently valued at roughly 11 times trailing earnings, with a dividend yield near 4.6%.

All eyes are on the Monetary Authority of Singapore’s policy review this Thursday. Most economists surveyed by Reuters predict no change to current settings. Edward Lee, chief economist at Standard Chartered, said there’s “no urgency to act” right now. But Bank of America economists warn MAS might tighten policy at this review if inflation shows signs of picking up. Instead of adjusting interest rates, MAS steers monetary conditions by managing the Singapore dollar within a trade-weighted policy band. Reuters

UOB is set to report its full-year 2025 financial results on Feb. 24, with the announcement coming before the market opens, according to an SGX filing. Investors will focus on any shifts in the bank’s approach to credit costs—the reserves for bad loans—and its fee income, following a turbulent year across the region.

The stock is still reacting after Monday’s drop in Singapore’s banking trio, which dragged the Straits Times Index down 0.6%. UOB took the biggest hit, closing Jan. 26 down 2.5% at S$38.50, reported.

On Jan. 25, JPMorgan downgraded UOB from “neutral” to “underweight,” keeping its target price steady at S$34, according to the Business Times. This followed a 5% jump in UOB shares on Jan. 23, when the stock closed at S$39.50 before starting to pull back. Meanwhile, Macquarie analyst Jayden Vantarakis upgraded UOB to “outperform,” setting a target of S$41 and pointing to wealth inflows driven by Singapore’s “safe-haven” status. The Business Times

Analysts Tay Wee Kuang and Lim Siew Khee at CGS International forecast UOB’s net profit for Q4 2025 to hit about S$1.28 billion, marking a 16.7% drop year-on-year. They linked this to a tougher comparison base following a one-off deferred tax expense in Q4 2024. The duo also pointed to softer wealth management and loan-related fees. Meanwhile, they expect credit costs to ease by 28 basis points from the previous quarter — with a basis point representing 0.01 percentage point. They warned of downside risks from a “weaker economic outlook for ASEAN” and potential extra provisioning tied to UOB’s exposure in Greater China’s commercial property sector. Asian Banking & Finance

UOB moved on wholesale funding, pricing A$2 billion ($1.39 billion) of senior unsecured notes in two tranches, according to FinanceAsia. This move highlights the bank’s ability to tap offshore debt markets while broadening its funding sources.

The share price’s next move could hinge on whether UOB manages to steer clear of another surge in provisions and maintain lending margins amid shifting rates. In November, the bank projected its 2026 net interest margin—the gap between loan earnings and deposit costs—would drop to 1.75%-1.80%, following a hefty S$1.36 billion in credit allowances booked in Q3.

Markets will get a near-term cue on Jan. 29, when MAS releases its quarterly monetary policy statement. UOB’s associate economist Jester Koh said there’s “little urgency to act now,” though some analysts expect a possible hawkish shift. Attention for UOB shares then turns to Feb. 24, the date set for its FY25/4Q25 earnings report. The Straits Times

Stock Market Today

  • Madison Air Solutions IPO Shows Strong Start Amid AI Data Center Cooling Demand
    May 15, 2026, 10:53 AM EDT. Madison Air Solutions, a profitable company serving the cooling needs of AI data centers, has seen its stock rise 28% since its April IPO. In 2025, the firm reported $124 million net income on $3.3 billion sales and posted a 33.8% sales increase in Q1 2026. Its backlog surged 115.5%, signaling robust demand for cooling services driven by data center heat management. However, risks include potential slowdown in AI data center expansion and the typical post-IPO volatility. Investors are advised to consider a cautious approach, possibly starting with a small stake while monitoring ongoing quarterly performance.

Latest articles

Plug Power Stock Drops Again: The $5 Billion Hydrogen Turnaround Faces Its Cash Test

Plug Power Stock Drops Again: The $5 Billion Hydrogen Turnaround Faces Its Cash Test

15 May 2026
Plug Power shares fell 1.7% to $3.725 in early Nasdaq trading Friday, following a volatile week after first-quarter results. The company reported a 22% revenue increase to $163.5 million and improved gross margin, but its net loss widened to $245.3 million and operating cash use rose to $150 million. Plug ended March with $802 million in cash and expects $142 million from a hydrogen asset sale in June.
Why Ford Motor Company Stock Is Sliding After Its AI Data Center Rally

Why Ford Motor Company Stock Is Sliding After Its AI Data Center Rally

15 May 2026
Ford shares dropped 7% to $13.43 in early Friday trading, reversing part of a rally sparked by the launch of its new Ford Energy unit. The subsidiary, announced this week, will sell large battery energy storage systems to utilities and data centers, with first deliveries expected in late 2027. CEO Jim Farley said Ford is in the contracting phase with several customers. The stock had surged 13% Wednesday after Morgan Stanley highlighted the business.
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

15 May 2026
Biogen has closed its acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and delisting its shares from Nasdaq. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains the drugs Empaveli and Syfovre, and expands into kidney disease. Biogen borrowed $2 billion to help finance the deal.
Nokia Oyj Stock Pulls Back After AI Rally: What Investors Need to Know

Nokia Oyj Stock Pulls Back After AI Rally: What Investors Need to Know

15 May 2026
Nokia’s U.S.-listed shares dropped about 5% Friday, trading at $13.74 after a recent AI-driven surge. The decline followed a rally sparked by Cisco’s report of $5.3 billion in AI infrastructure orders from hyperscalers. Nokia saw a 54% jump in first-quarter operating profit and named Siemens’ Emma Falck as president of Mobile Infrastructure, effective September 1.
Wilmar stock pops 4% in Singapore as palm oil prices firm — what to watch next
Previous Story

Wilmar stock pops 4% in Singapore as palm oil prices firm — what to watch next

Unilever stock price today: ULVR nudges up as Goldman trims target, results loom
Next Story

Unilever stock price today: ULVR nudges up as Goldman trims target, results loom

Go toTop